Stockscreener 앱 받기
39.06
0.74%
-0.29
시간 외 거래:
39.05
-0.01
-0.03%
전일 마감가:
$39.35
열려 있는:
$39.25
하루 거래량:
6.73M
Relative Volume:
0.69
시가총액:
$172.38B
수익:
$50.91B
순이익/손실:
$18.95B
주가수익비율:
9.1669
EPS:
4.261
순현금흐름:
$1.92B
1주 성능:
+2.47%
1개월 성능:
-1.86%
6개월 성능:
-0.91%
1년 성능:
-28.70%
1일 변동 폭
$39.05
$39.49
1주일 범위
$38.35
$39.68
52주 변동 폭
$35.12
$64.16
노보 노디스크 Stock (NVO) Company Profile
Compare NVO vs LLY, JNJ, ABBV, MRK, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
39.06 | 172.38B | 50.91B | 18.95B | 1.92B | 4.261 |
LLY
Lilly Eli Co
|
1,270.75 | 1.13T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
257.78 | 621.22B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
284.80 | 503.28B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
149.88 | 369.78B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
153.93 | 292.58B | 54.66B | 13.58B | 16.05B | 7.0171 |
노보 노디스크 Stock (NVO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-09-11 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2026-08-27 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2026-08-12 | 다운그레이드 | Berenberg | Buy → Hold |
| 2026-03-26 | 개시 | Wolfe Research | Peer Perform |
| 2026-03-18 | 개시 | Bernstein | Outperform |
| 2026-03-10 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2026-03-03 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2026-03-02 | 다운그레이드 | Goldman | Buy → Neutral |
| 2026-02-24 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2026-02-24 | 다운그레이드 | Kepler | Buy → Hold |
| 2026-02-23 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2026-02-12 | 업그레이드 | Jefferies | Underperform → Hold |
| 2026-01-27 | 개시 | Citigroup | Neutral |
| 2025-12-08 | 다운그레이드 | Argus | Buy → Hold |
| 2025-10-27 | 재개 | Jefferies | Underperform |
| 2025-10-01 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2025-09-29 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2025-09-17 | 업그레이드 | Berenberg | Hold → Buy |
| 2025-09-16 | 업그레이드 | Rothschild & Co Redburn | Neutral → Buy |
| 2025-09-09 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2025-08-13 | 업그레이드 | BNP Paribas Exane | Underperform → Neutral |
| 2025-08-05 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-07-31 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2025-07-30 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-04-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2025-03-13 | 업그레이드 | Kepler | Hold → Buy |
| 2025-03-03 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-02-12 | 개시 | Morgan Stanley | Equal-Weight |
| 2025-01-06 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-04-12 | 개시 | BMO Capital Markets | Outperform |
| 2024-01-23 | 개시 | Morgan Stanley | Overweight |
| 2024-01-16 | 재개 | UBS | Neutral |
| 2023-12-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-02 | 개시 | Argus | Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2022-07-15 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-06-28 | 다운그레이드 | UBS | Neutral → Sell |
| 2022-06-27 | 업그레이드 | Exane BNP Paribas | Underperform → Neutral |
| 2022-06-07 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-05-31 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-04-25 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2022-04-12 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-03-16 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2022-01-25 | 다운그레이드 | Liberum | Hold → Sell |
| 2021-12-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-12-17 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2021-01-20 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2021-01-15 | 개시 | Deutsche Bank | Buy |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-07-06 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-05-11 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-05-04 | 개시 | Cowen | Market Perform |
| 2020-03-16 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2020-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-11-18 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-09-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-08-30 | 다운그레이드 | Jefferies | Hold → Underperform |
| 2019-06-20 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2019-06-11 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2019-04-29 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-01-29 | 개시 | Exane BNP Paribas | Outperform |
| 2018-12-11 | 재개 | Jefferies | Hold |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2017-12-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2017-12-06 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2017-12-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-25 | 다운그레이드 | Exane BNP Paribas | Outperform → Neutral |
| 2017-09-06 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
모두보기
노보 노디스크 주식(NVO)의 최신 뉴스
Global Oral Drugs Market is Predicted to Surpass USD 1 Trillion Mark by 2034 | DelveInsight - GlobeNewswire Inc.
How Will Novo's GLP-1 Portfolio Sales Aid Upcoming Q3 Results? - Zacks Investment Research
Novo's CagriSema Delivered 25% Weight Loss in Women. Could It Help Turn Around the Beaten-Down Stock? - The Motley Fool
Bet on This New GLP-1 ETF to Gain Exposure to a Booming Market - Zacks Investment Research
$Novo-Nordisk A/S (NVO.US)$ A bullish breakout above the 25-day moving average carries a 70% probability of further upside. It is even more favorable if today's closing price is higher than yesterday's and there is no upper shadow. - Moomoo
Metabolic Dysfunction-Associated Steatohepatitis Clinical Trial and Competitive Landscape Expands as 180+ Companies Target New Treatment Options | DelveInsight - GlobeNewswire Inc.
How Investors May Respond To Novo Nordisk (CPSE:NOVO B) Obesity Drug Competition - Yahoo Finance
Novo Nordisk Stock (NVO) Climbs 2% Today on Positive CagriSema Weight-Loss Data - TipRanks
Novo's CagriSema helped women lose 25% of weight on average, analysis shows - Reuters
Prothena's Partnership Strategy: Growth Driver or Limitation? - Zacks Investment Research
Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis - CNBC
Denmark’s Novo-Fueled Economy Faces Lower Growth, Watchdog Says - Bloomberg.com
Price to earnings forward of Novo Nordisk A/S Class B – LSIN:0QIU - TradingView
Novo Nordisk (NVO) Stock Sinks As Market Gains: Here's Why - Zacks Investment Research
Novo Nordisk (NVO) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market - The Motley Fool
How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q3 Results? - Zacks Investment Research
Novo Nordisk (NVO) repurchased 39.1 million B shares; treasury shares total 1.2% of share capital. - Stock Titan
Is Trending Stock Novo Nordisk A/S (NVO) a Buy Now? - Zacks Investment Research
Is Trending Stock Novo Nordisk A/S (NVO) a Buy Now? - Yahoo Finance
Novo Nordisk A/Sshare repurchase programme - GlobeNewswire
Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter. - The Motley Fool
The Nasdaq-100's 6 Best Stocks This Year, and Whether They Can Keep Going - The Motley Fool
Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's Next Leg Higher - The Motley Fool
Novo Nordisk and Eli Lilly Just Got Some Fantastic News - The Motley Fool
Novo Nordisk A/S (NVO) options chain - Yahoo Finance Australia
Novo-Nordisk A/S (NVO) Stock Forum and Discussion - Moomoo
Novo Nordisk A/S Tokenized Stock (Coinbase) Price Today - CryptoRank
Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.
Viking Therapeutics Starts Phase III Development of Obesity Pill - Zacks Investment Research
Novo Nordisk A/S : UBS remains Neutral - marketscreener.com
Novo Nordisk (NVO) Could Be 63% Undervalued Following Its Share Buyback - Yahoo Finance
Roche Expands Obesity Pipeline With Rona's RNAi Candidate - Zacks Investment Research
Is Novo Nordisk (NYSE:NVO) A Long Term Value Opportunity Now? - Yahoo Finance
The Zacks Analyst Blog Highlights Walmart, Visa, Novo Nordisk, Village Super Market and Empire Petroleum - Zacks Investment Research
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Why Novo Nordisk (NVO) Dipped More Than Broader Market Today - Zacks Investment Research
Why Novo Nordisk (NVO) Dipped More Than Broader Market Today - Yahoo Finance
Top Analyst Reports for Walmart, Visa & Novo Nordisk - Zacks Investment Research
Top Analyst Reports for Walmart, Visa & Novo Nordisk - Yahoo Finance
Novo Nordisk A/S: Dividend historical data and projections - marketscreener.com
GLP-1 weight-loss drugs slow biological aging, recent studies show - NewsNation
Novo Nordisk Details Progress in DKK 15 Billion Share Buyback Programme - TipRanks
Buybacks total 37.8M B shares at Novo Nordisk (NVO), under a programme capped at DKK 15B. - Stock Titan
Eli Lilly Expects Up to $87 Billion in 2026 Revenue. Here's Why the Stock Still Looks Undervalued. - The Motley Fool
Novo Down 11% in a Month: How Should Investors Approach the Stock Now? - Zacks Investment Research
4 Healthcare Stocks Worth Owning for the Next Decade - The Motley Fool
Novo Nordisk price target lowered to $40 from $47 at BMO Capital - TipRanks
BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Hold Rating, Cuts Target Price to $40 - Moomoo
Pfizer Moves Past 50-Day SMA: Time to Buy, Hold or Exit the Stock? - Zacks Investment Research
노보 노디스크 (NVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.86%
자본화:
|
볼륨(24시간):